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Carboxypeptidase G2 (CP) is a bacterial enzyme, which is targeted to tumours by an antitumour antibody for local prodrug activation
in antibody-directed enzyme prodrug therapy (ADEPT). Repeated cycles of ADEPT are desirable but are hampered by human
antibody response to CP (HACA). To address this, we aimed to identify and modify clinically important immunogenic sites on
MFECP, a recombinant fusion protein of CP with MFE-23, a single chain Fv (scFv) antibody. A discontinuous conformational epitope
at the C-terminus of the CP previously identified by the CM79 scFv antibody (CM79-identified epitope) was chosen for study.
Modification of MFECP was achieved by mutations of the CM79-identified epitope or by addition of a hexahistidine tag (His-tag) to
the C-terminus of MFECP, which forms part of the epitope. Murine immunisation experiments with modified MFECP showed no
significant antibody response to the CM79-identified epitope compared to A5CP, an unmodified version of CP chemically conjugated
to an F(ab)2 antibody. Success of modification was also demonstrated in humans because patients treated with His-tagged MFECP
had a significantly reduced antibody response to the CM79-identified epitope, compared to patients given A5CP. Moreover, the
polyclonal antibody response to CP was delayed in both mice and patients given modified MFECP. This increases the prospect of
repeated treatment with ADEPT for effective cancer treatment.
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Antibody-directed enzyme prodrug therapy (ADEPT) is an
experimental cancer treatment in which an enzyme linked either
chemically or genetically to tumour-targeting antibody is given
intravenously. When the antibody–enzyme has cleared from the
circulation, a prodrug is given and is converted to active drug in
the tumour by the targeted enzyme (Bagshawe et al, 1988). An
illustration of the ADEPT concept is shown in Figure 1. ADEPT
aims to overcome the shortcomings of systemic cancer treatment
such as lack of tumour selectivity and drug resistance. Clinical
ADEPT studies (Bagshawe et al, 1995; Napier et al, 2000; Francis
et al, 2002) have used the bacterial enzyme carboxypeptidase G2
(CP) conjugated to A5B7, a monoclonal anticarcinoembryonic
antigen (CEA) F(ab)2. This antibody–enzyme conjugate, termed
A5CP, has demonstrated feasibility of ADEPT and evidence of
therapeutic response in patients with advanced CEA-expressing
adenocarcinomas. The use of CP has advantage over human
enzymes in that there is no human enzyme with equivalent
substrate specificity so that the danger of prodrug activation by
host enzyme is avoided. However, the development of human
anti-CP antibody (HACA) and human anti-mouse antibody
(HAMA) was a serious limitation of ADEPT with A5CP. HACA
were observed in 97% and HAMA in 100% after single
administration of A5CP (Napier et al, 2000; Francis et al, 2002).
Hence, methods of reducing immunogenicity of the antibody–
enzyme molecule are required since neutralising antibodies can
inactivate therapeutics (Baert et al, 2003) and are potentially
detrimental to the patient. Furthermore, protein therapeutics are
of increasing importance in the treatment of cancer, so a means to
reduce antibody response is likely to be applicable to other
therapeutic proteins.
This manuscript explores modification of immunogenic B-cell
epitopes as a way to address immunogenicity of protein
therapeutics. It was postulated that identification and silencing
of epitopes recognised by the human immune system could allow
repeated treatment with ADEPT if these epitopes could be
disrupted without compromise of enzyme activity. Previously, we
developed a system for identifying B-cell epitopes and applied it to
identify a discontinuous conformational epitope on CP with the
CM79 scFv antibody (CM79-identified epitope; Spencer et al, 2002)
(Figure 2). In the current paper we modify the CM79-identified
epitope to test our hypothesis.
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sThe antibody–enzyme molecule chosen for our studies is
MFECP, a fusion protein of CP with the single–chain Fv anti-
CEA antibody, MFE-23 (Chester et al, 1994; Mayer et al, 2000).
MFECP contains the same CP as A5CP but has advantage over
A5CP in that MFECP is a recombinant molecule and therefore
readily manipulated to disrupt the CM79-identified epitope.
Modification of the CM79-identified epitope on the CP moiety of
MFECP is proposed as a means of producing a recombinant
antibody–enzyme fusion protein which retains activity but lacks
the B-cell epitope. This was addressed firstly, by inserting
mutations into region 1 (amino acids 157–163) and region 2
(amino acids 412–415) of the CM79-identified epitope and
secondly by adding a His-tag to the C-terminus, which comprises
part of region 2 (Figure 2). The success of these modifications has
been tested by measuring retention of enzyme activity, testing
reactivity with immune murine and human sera, investigating
potential for repeated therapy in mice and, with one of the
constructs, in a clinical trial.
MATERIALS AND METHODS
Construction, expression and purification of proteins in
Escherichia coli
Details of plasmid constructs are shown in Figure 3. Construction
of pPM331 (encoding MFECP, a recombinant fusion protein of the
anti-CEA scFv MFE-23 and CP, an enzyme derived from
Variovorax paradoxus, formerly Pseudomonas sp RS 16) has been
described previously (Michael et al, 1996). Plasmid pDP161
(encoding MFEdmCP) is identical to MFECP except for a mutation
in both regions encoding the discontinuous immunodominant
epitope of CP (R162A and G412A) (Spencer et al, 2002). This
plasmid was created by isolating a 244bp SalI/EcoRI fragment
from the previously constructed vector carrying G412A (pDP132),
and inserting it between the equivalent sites of plasmid pDP130,
which carries R162A. This SalI site corresponds to that found at
position 1204 of the CP gene (Accession No. M12599), whereas the
EcoRI site was created immediately following the TGA stop codon.
In relation to Accession No. M12599, the nucleotide substitutions
resulting in alanine replacement equate to substitution of CGC (nt
678–680) with GCG (R162A), and substitution of the G at nt 1429
with C (G412A). The pPM331 and pDP161 plasmids were
expressed in E. coli TG1 cells and MFECP and MFEdmCP protein
were purified on activated CH Sepharose 4B crosslinked to CEA as
described previously (Bhatia et al, 2000). The eluted samples were
pooled and dialysed overnight against four changes of PBS and
20 concentrated at 41C in a stirred cell ultrafiltration system
(Amicon, UK) using a YM10 membrane (Millipore, UK). Further
purification was carried out by size exclusion chromatography
using a 120ml Superdex 200 column on an automated A ¨KTA
purification system (Amersham Pharmacia Biotech, UK). Samples
were concentrated to approximately 0.15mgml
 1 and stored at
 801C. Purity and identity were confirmed by sodium dodecylsul-
phate–polyacrylamide gel electrophoresis (SDS – PAGE) and
Western blot, CEA binding was confirmed by enzyme-linked
immunosorbent assay (ELISA) (Bhatia et al, 2000).
Construction, expression and purification of proteins in
Pichia pastoris
MFECP was subcloned into the E. coli/P. pastoris shuttle vector
pPICZaB to enable expression in P. pastoris. A His-tag was
engineered at the C-terminus of MFECP to facilitate purification
Figure 1 In the first stage of ADEPT, the intravenously administered antibody–enzyme fusion protein MFECPHis is allowed to localise in the tumour. In
the second stage, prodrug ZD2767P, based on a bis-iodo-phenol mustard is given after clearance of enzyme from the circulation. CP cleaves the glutamate
moiety to generate the active drug ZD2767D.
Figure 2 Model of CP showing the discontinuous CM79-identified
epitope (region 1 residues 157–163: KEYGVRD coloured in blue, region 2
residues 412–415 coloured in red). The graphic representation was
produced with MOLMOL (Koradi et al, 1996).
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susing immobilised metal affinity chromatography (IMAC). The
resultant plasmid construct (pPIC001) is shown in Figure 3.
Plasmid pPIC002 is identical to pPIC001 except that it harbours
the sequence encoding MFEdmCP instead of MFECP. A His-tag-
encoding sequence was added to the MFEdmCP-encoding
sequence on pDP161 via PCR. Two primers (Sigma Genosys,
UK) were used: a 50 primer (31bp) that was designed to amplify
the sequence from position 1696, starting 18 bp upstream of the
SalI site (MFECP-sense, 50GAA GGC GGC AAG AAG CTG GTC
GAC AAG GCG G) and a 30 primer (CP-dmXbaHis anti-sense,
30ACC TGT AAC TGC AGA ATT CTA GAT TAT TAA TGG TGA
TGA TGG TGA TGC TTG CCG GCG GCC AGA TCC ATG) which
was complementary from position 1929 to 1947. Additional
sequence was added to encode a His-tag, EcoRI (underlined) and
XbaI (bold) sites and an additional tail to enhance cloning. EcoRI/
SalI digestion of pDP161 was performed prior to amplification by
polymerase chain reaction (PCR). Reaction mixture comprised: 10
pmol MFECP-sense and 10 pmol CP-dm-XbaHis anti-sense
primer, 128mM dNTPs (Applied Biosystems, UK), 2.5 U Taq
Polymerase (Applied Biosystems, UK) and 10ml1 0  reaction
buffer containing 15mM MgCl2 (Applied Biosystems, UK) in a final
reaction volume of 100ml. Five minutes at 95
oC were followed by
30 PCR cycles consisting of 1min at 941C, 1min at 751C, 1min at
721C and a final extension time of 7min at 72
oC. The PCR product
was purified with Wizard PCR preps DNA purification kit
(Promega, UK) according to the manufacturer’s instructions and
ligated into pCR2.1TOPO (Invitrogen, UK) for nucleotide sequence
confirmation (MWG Biotech, Germany). The new plasmid was
digested with EcoRI/SalI and the excised fragment was religated
into the complementary sites of pDP161 yielding pDP161His.
Finally, pDP161His was digested with XbaI and SfiI and the
fragment encoding MFEdmCPHis was ligated into the comple-
mentary sites of pPICZaB yielding pPIC002 (encoding MFEdmC-
PHis).
The constructs pPIC001 (MFECPHis) and pPIC002 (MFEdmC-
PHis) were linearised with PmeI, electroporated into P. pastoris
X33 on a gene pulser (Biorad, UK) and plated on YPDS agar (1%
yeast extract, 2% peptone (Difco, UK) 2% glucose (Sigma, UK),
1M sorbitol (Sigma, UK), 2% agar (Difco, UK)) containing
100mgml
 1 Zeocin (Invitrogen, UK). The correct insert was
confirmed by PCR screening and nucleotide sequence confirma-
tion (MWG Biotech, Germany). Cells were treated with lyticase
(5Uml
 1; Sigma, UK) to break the yeast cell wall prior to the PCR
with 25pmol 50AOX1 primer and 25pmol 30AOX1 primer
(Invitrogen, UK), 5ml1 0   reaction buffer containing 15mM
MgCL2,6 4mM dNTP, 5U Taq polymerase and 5ml cell lysate in a
final volume of 50ml. Five minutes at 951C were followed by 30
PCR cycles of 1min at 951C, 1min at 541C and 1min at 721C with a
final extension time of 7min at 721C. A seed lot was prepared, one
colony was grown in shake flasks with 20ml YPD at 301C (1% yeast
extract, 2% peptone, 2% glucose) until an optical density of 25 at
600nm was reached, cells were spun for 10min at 4000r.p.m.,
resuspended in YPD containing 15% glycerol and frozen at  801C.
Large scale production of P. pastoris X33::pPIC001 or P. pastoris
X33::pPIC002 expressing MFECPHis or MFEdmCPHis, respec-
tively, were performed. A 2-l shake flask containing 200ml YEPD/
glucose medium (1% yeast extract, 2% peptone and 1.5% glucose)
was inoculated with 1ml of seed lot and incubated overnight at
301C in an orbital shaker at 250r.p.m. Subsequently, 5ml of this
culture was used to inoculate a second 2-l shake flask containing
330ml of minimal fermentation medium (0.857g CaSO4 (BDH,
UK), 13.90g K2SO4 (Sigma, UK), 11.14g MgSO4 7H 2O (Sigma,
UK), 8.57g (NH4)2SO4 (BDH, UK), 47.6ml glycerol (BDH, UK),
23.8g NaPO3 (BDH, UK) and 3.8ml trace element solution
(Amresco, UK)). Incubation was continued as before. This culture
was used to inoculate a fermentor (Bioflow 3000, New Brunswick,
UK). Fermentation was performed at 301C, pH 5 and regulated by
titration with 100% NH4OH (Sigma, UK), 10% H3PO4 (BDH, UK)
and 40% dissolved oxygen. After depletion of glycerol (carbon
source) the pH was shifted to 6.5, and a limited glycerol feed was
initiated, which was subsequently replaced by a limited methanol
feed of 45mlh
 1 to induce expression of fusion proteins via the
AOX promoter. Cells were harvested after 72h by centrifugation at
4000r.p.m. and 1l of supernatant was purified by IMAC (Casey
et al, 1995) on a 30ml chelating sepharose fast flow column loaded
with 0.1M CuSO4. Endotoxins were removed on a 10ml polymyxin
column (Pierce, UK) according to the manufacturer’s instructions.
SDS – PAGE, Western blot and ELISA were performed to confirm
expression of the correct protein and binding to CEA (Bhatia et al,
2000).
Catalytic activity of CP
Carboxypeptidase G2 cleaves methotrexate (MTX) to give measur-
able changes in absorbance, which are related to enzyme
concentration. This change in absorbance of MTX after CP
pPIC001 (MFECPHis)
pPIC002  (MFEdmCPHis) 
MFE-23 CP -Factor AOX
AOX
P
 His
MFE-23 CP -Factor
P
  His
pDP161      (MFEdmCP) 
MFE-23 CP PelB  lacZ  P
pPM331     (MFECP) 
MFE-23 CP PelB  lacZ  P
E. coli  expression 
P.pastoris  expression 
A
B
Figure 3 Schematic representation of the variants of MFE-CP. Panel A illustrates the genetic constructs of the fusion proteins expressed in E. coli after
transfection with pPM331 (MFECP) and pDP161 (MFEdmCP), panel B the fusion proteins expressed in P. pastoris with a C-terminal His-tag after
transfection with pPIC001 (MFECPHis) and pPIC002 (MFEdmCPHis).
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shydrolysis was measured by spectrophotometry at 320nm (Beck-
man DU-64 spectrophotometer, Soft Pac Module KINETICS
Software Package, Beckman Instruments Ltd, Bucks, UK) as
previously described (Minton et al, 1984). Measurements were
performed in duplicate, 10ml of sample were incubated in 1ml of
assay buffer (100mM Tris-HCl, pH 7.3, 0.2mM ZnSO4 and 60mM
MTX) at 371C. Enzyme activity was expressed in units (U), where
1U is the amount of enzyme required to hydrolyse 1mmol of MTX
per minute at 371C. Carboxypeptidase G2 (1000Uml
 1) was used
as reference standard.
CM79 scFv antibody
The anti-CP scFv antibody CM79 was expressed in E. coli TG1 cells
with a C-terminal His-tag for purification on IMAC as described
previously (Spencer et al, 2002). The cell-free supernatant was
concentrated and purified on IMAC (Casey et al, 1995) on an
automated A ¨KTA purification system with a final yield of purified
CM79 of approximately 12mgl
 1 culture supernatant. Purity and
identity were confirmed by SDS–PAGE and Western blot. A band
at the expected molecular weight of 27kDa consistent with CM79
was detected (data not shown). The purified CM79 antibody was
used in a competition ELISA to measure the proportion on
immunised mice antibodies that were directed against the CM79-
identified epitope (ELISA E). For later experiments, CM79 was
biotinylated using the ECL biotinylation kit (Amersham, UK)
according to the manufacturer’s instruction. In order to check that
CM79 antibody binding was not compromised by biotinylation,
the binding of biotinylated and nonbiotinylated CM79 was
compared using ELISA (A). Biotinylated CM79 antibody was also
used to test disruption of the CM79-identified epitope in ELISA (B)
and in competition assays to measure the proportion of human
antibodies that were directed against the CM79-identified epitope
in ELISA (C).
Murine immunisation studies
Two separate experiments were performed, the first comparing
MFECPHis (endotoxin o0.1EUml
 1). and MFEdmCPHis (en-
dotoxin 1.1EUml
 1) and the second experiment comparing
MFECPHis and A5CP (endotoxin o0.1EUml
 1). A5CP was
supplied by Lonza Biologics (UK) for the previous clinical trial
(Francis et al, 2002) and consists of an F(ab0)2 derived from the
affinity-purified monoclonal anti-CEA antibody A5B7 covalently
linked to CP (Melton et al, 1993). Groups of eight Balb/c mice were
injected 4  intraperitoneally (i.p.) with 50mg A5CP, MFECPHis or
MFEdmCPHis every 14 days. Mice were bled prior to each
injection and 14 days after the final injection. All experiments were
performed with ethical committee approval and met the standards
of the UK Coordinating Committee on Cancer Research Guidelines
for the welfare of animals (Workman et al, 1998). The resulting
murine antibody response to CP was assessed using ELISA (D).
Murine antibody formation to the CM79-identified epitope was
assessed using ELISA (E).
Human immune response
Sera were obtained between 21 and 43 days after treatment with
3000Um
 2 A5CP (Francis et al, 2002) or 5000Um
 2 MFECPHis
followed by the prodrug ZD2767P for ADEPT. Both studies were
approved by the local research ethics committee and informed
consent was obtained from all patients. HACA formation in
patients was measured by ELISA (F). Three standard deviations
were added to the mean of a pool of pretreatment sera diluted
1/100 to give the cutoff for HACA-positive sera. The proportion of
HACA that was directed to the CM79-identified epitope was
measured by competion ELISA (G).
ELISAs
The CP-binding capacity of human, murine and scFv antibodies
was measured by ELISA. Samples in all ELISAs were applied in
duplicate. Blocking to prevent unspecific binding was performed
overnight with 5% milk powder in 0.1% Tween 20 in PBS
containing 0.02% NaN2 at 41C. Incubation times of sera and
antibodies were 1h at room temperature and wash steps consisted
of 2 PBS/0.1% Tween 20 followed by 4 H2O. Peroxidase (POX)
was detected with o-phenyldiamine (Sigma, UK) in phosphate-
citrate buffer with sodium perborate (pH 5; Sigma, UK), the
reactions were quenched after 5min reaction time with 4 M HCl
and plates were read at 490nm. Alkaline phosphatase (AP) was
detected in all ELISAs with p-nitrophenylphosphate (Sigma, UK) in
0.1 M glycine buffer (1mM MgCl2,1m M ZnCl2; pH 10.4) and plates
were read at 405nm on an automated plate reader (Thermo Life
Sciences, UK) after 15min reaction time. Individual ELISA
methods varied in order to measure the following:
ELISA (A): CP binding of biotinylated CM79 antibody Binding of
biotinylated and nonbiotinylated CM79 antibody was compared by
ELISA on CP-coated plates (10mgml
 1 in carbonate bicarbonate
buffer pH 9.2; Sigma, UK). Ten-fold serial dilutions of biotinylated
and nonbiotinylated CM79 (6.5mgml
 1) were added, followed by
anti-His antibody (1/500; Qiagen, UK) and POX-labelled sheep
anti-mouse antibody (1/1000; Sigma, UK).
ELISA (B): Disruption of CM79-identified epitope Reactivity of
fusion proteins with CM79 was tested on plates coated with CEA
(1mgml
 1 in PBS). Fusion proteins (150ngwell
 1) were applied
prior to biotinylated CM79 (1.3, 0.65 and 0.13mgml
 1). This was
followed by incubation with Extravidin AP (1/5000; Sigma, UK).
ELISA (C): Clinical relevance of CM79-identified epitope Clinical
relevance of CM79-identified epitope was tested by comparing the
immunoreactivity of HACA positive patients’ sera with MFECP
and MFEdmCP on plates coated with CEA (1mgml
 1 in PBS)
followed by MFECP or MFEdmCP (0.75mgml
 1). This was
followed by incubation of 10-fold serial dilutions of HACA positive
sera after treatment with A5CP and by AP-labelled anti-human g-
chain F(ab)2 antibody (1/10000; Sigma, UK). Reactivity of
individual sera with MFECP and MFEdmCP was tested on the
same plate. Plates were read after 30min reaction time.
ELISA (D): Murine polyclonal anti-CP response Mouse antibodies
to CP were measured on plates coated with CP (10mgml
 1 in
carbonate bicarbonate buffer pH 9.2; Sigma, UK). Incubation with
mouse sera (diluted 1/100) was followed by AP-labelled anti-mouse
Fc antibody (1/2500; Sigma, UK). Ten-fold serial dilutions of the
monoclonal anti-CP antibody SB43 (3mgml
 1) was used as
positive control. Plates were read after 30min reaction time.
ELISA (E) CM79 antibody competition with immunised mouse
sera The ability of immunised mouse sera to compete with CM79
antibody was tested on CP-coated plates in a competitive binding
assay. Comparison of binding of polyclonal anti-CP antibodies in
the presence and absence of CM79 antibody was measured. Mouse
sera (diluted 1/100) were applied with and without CM79 antibody
(25mgml
 1), AP labelled anti-mouse Fc antibody (1/2500; Sigma,
UK) was used for detection of binding of polyclonal anti-CP
antibodies in the presence and absence of CM79 antibody.
ELISA (F): HACA formation in patients The human polyclonal
response to CP after treatment with A5CP was measured by ELISA
on CP-coated plates as described previously (Sharma et al, 1992).
Briefly, HACA formation in patients after MFECPHis was
measured on CP coated plates (10mgml
 1 in carbonate bicarbo-
nate buffer pH 9.2; Sigma, UK). Incubation of 10-fold serial
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sdilutions of sera was followed by POX-labelled anti-human g-chain
F(ab)2 antibody (1/2000; Sigma, UK).
ELISA (G): CM79 antibody competition with immunised human
sera ELISAs were carried out on (a) CP (10mgml
 1 in carbonate
bicarbonate buffer pH 9.2; Sigma, UK)-coated plates and (b) CEA
(1mgml
 1 in PBS)-coated plates followed by A5CP or MFECPHis
(150ngwell
 1) to ensure that the result was not influenced by a
conformational change on CP-coated plates. Patients’ sera (1/100)
were spiked with biotinylated CM79 antibody (0.65mgml
 1). Sera
were subsequently applied, in both assays, in 10-fold serial
dilutions, followed by incubation with Extravidin AP (1/5000).
Inhibition of CM79 antibody binding was taken as evidence that
patients’ sera had antibodies directed against the CM79-identified
epitope. Binding of biotinylated CM79 antibody in spiked patients’
sera was compared to binding of biotinylated CM79 antibody in
the presence of HACA-negative serum.
Statistics
A paired Student’s t-test was used to compare binding of post-
treatment sera to MFECP and MFEdmCP and binding of CM79 to
fusion proteins. The anti-CP antibody response in the murine
immunisation studies and HACA formation in patients after
administration of A5CP and MFECPHis was compared by Fisher’s
exact test. Wilcoxon signed ranks test was used to compare the
murine antibody response to the CM79-identified epitope. An
unpaired Student’s t-test assuming equal variances was used for
the comparison of the immune response to the CM79-identified
epitope after treatment with A5CP and MFECPHis.
RESULTS
Modification of the CM79-identified epitope by mutation
The immunogenic CM79-identified B-cell epitope of CP was
modified by mutating both of its discontinuous regions on the
MFECP fusion protein. Region 1 of the CM79-identified epitope
that spans amino acids 157–163 was modified by changing
arginine 162 to alanine (R162A), Region 2, which spans amino
acids 412–415 at the C-terminus of the molecule was modified by
changing glycine 412 to alanine (G412A). The resulting double
mutant of the MFECP fusion protein was termed ‘MFEdmCP’.
MFEdmCP was expressed in E. coli and purified by affinity
chromatography on CEA followed by size exclusion chromato-
graphy. MFECP, which contains wild-type CP but is identical to
MFEdmCP in all other aspects, was expressed and purified in
parallel experiments. Analysis by SDS–PAGE and Western blot
confirmed expression of MFECP and MFEdmCP as illustrated in
Figure 4 where a major band is shown at 68.5kDa, the expected
molecular weight of the fusion protein. The final yield after
purification was low, as only 0.13mgl
 1 of supernatant were
recovered for MFECP and 0.1mgl
 1 for MFEdmCP. However,
there was no loss of enzymatic activity despite the two mutations,
because when the purified proteins were tested for catalytic activity
188Umg
 1 was measured for MFECP and 210Umg
 1 for
MFEdmCP.
The CM79-identified epitope is defined by its binding to anti-CP
scFv antibody CM79. Successful modification of the epitope is
therefore measured by reduction or ablation of binding to CM79
antibody. To test whether this had occurred, 10-fold serial
dilutions of the fusion proteins were reacted with CM79 antibody
using ELISA on CEA coated wells. The results showed that CM79
antibody binding to MFEdmCP was reduced by 99% compared to
MFECP (P¼0.00006, paired Student’s t-test, Table 1). These
results indicate successful modification of the CM79-identified
epitope by the R162A and G412A mutations because these ablated
CM79 antibody binding but did not affect catalytic activity.
Clinical relevance of the CM79-identified epitope
To test whether the modified CM79-identified epitope was
recognised by the human immune system MFEdmCP was reacted
with serum samples from 12 patients who had made antibodies to
CP as a result of receiving ADEPT with A5CP in a previous clinical
trial. Serum samples were taken 21–35 days after treatment. For
these experiments, MFEdmCP or MFECP was captured on CEA-
coated wells and reacted with individual patient’s sera. Results
showed that all these sera had lower binding to MFEdmCP than to
the unmutated MFECP. The antibody binding in this patient group
was reduced by a median of 15.2% (s.d.711.2%) and was
statistically significant (P¼0.0002, paired Student’s t-test). The
results indicated that the CM79-identified epitope is immunogenic
in humans because a significant portion of the human polyclonal
antibody response appeared to be directed to this epitope.
Modification of the CM79-identified epitope by addition of
a His-tag
Bacterial expression of MFECP and of MFEdmCP gave sufficient
material to confirm clinical relevance of the CM79-identified
epitope but did not provide a practical means of obtaining large
quantities of endotoxin-free fusion proteins for immunogenicity
experiments in mice and for clinical trials. This was achieved by
expression in the methotropic yeast P. pastoris under controlled
conditions in a fermentor. A C-terminal His-tag was added to
facilitate large-scale purification via metal affinity chromatogra-
phy, bypassing the need for CEA-affinity chromatography. His-
tagged, P. pastoris expressed, MFECP was termed MFECPHis and
His-tagged, P. pastoris expressed, MFEdmCP was termed
MFEdmCPHis. These fusion proteins were purified by IMAC.
Analysis of purified proteins by SDS–PAGE and Western blot
(Figure 4C and D) confirmed expression of MFECPHis and
MFEdmCPHis. Both proteins were tested for enzyme activity and
the presence of endotoxin. Results showed that the endotoxin
content was o0.1 and 1.1EUml
 1 for MFECPHis and MFEdmC-
PHis, respectively. The yields obtained with the P. pastoris system
were substantially higher than those obtained with E. coli,
11mgl
 1 supernatant for MFECPHis and 12mgl
 1 supernatant
for MFEdmCPHis, respectively. The enzyme activity was less than
for bacterially expressed fusion proteins, that is, 106Umg
 1
MFECPhis and 42Umg
 1 MFEdmCPhis.
The CM79 binding ELISA was applied to test for the presence of
the CM79-identified epitope on MFECPHis and MFEdmCPHis as
previously applied to test the untagged E. coli versions of these
fusion proteins. Results, shown in Table 1 demonstrated that, as
for MFEdmCP, the CM79 antibody binding to MFEdmCPHis was
reduced by 99% (s.d.70.45%) compared to MFECP (P¼0.00006,
paired Student’s t-test, Table 1). However, MFECPHis was also
shown to have reduced reactivity (54%; s.d.72.1%) with the CM79
Table 1 Binding of biotinylated CM79 to MFECP, MFEdmCP and
MFECPHis
Fusion protein CM79 binding
a (%)
MFECP (no tag) 100
MFEdmCP (no tag) 0.8
b
MFECPHis (His-tag) 54
b
MFEdmCPHis (His-tag) 0.9
b
aMeasured by ELISA on CEA-coated plates. Binding of biotinylated CM79 was
detected by Extravidin AP.
bBinding of MFEdmCP, MFECPHis and MFEdmCPHis
expressed as percentage of binding of MFECP.
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santibody in comparison to MFECP (P¼0.0006, paired Student’s t-
test), although the CM79 site was unmodified. This suggested a
masking of the CM79 site by the His-tag and was consistent with
the His-tag conferring an independent modification on the CM79
B-cell epitope.
Murine immune response to the CM79-identified epitope
Mouse immunisation experiments were performed to test the
hypothesis that the His-tag masked the CM79-identified epitope.
In one experiment, the immunogenicity of His-tag modified CP
was compared with that of unmodified CP in serum of mice
immunised with 50mg MFECPHis or 50mg A5CP. In a separate
experiment, the immunogenicity of His-tag-modified CP was
compared with that of CP that had been modified by His-tag and
mutation. In this case, mice were immunised with 50mg MFECPHis
or 50mg MFEdmCPHis. In both experiments, immunisations were
performed every 14 days and mice were bled prior to each
injection and after the final injection. A CM79-competition ELISA
was designed to measure if anti-CP antibodies formed in response
to these immunisations were directed to the CM79-identified
epitope. Results of this ELISA indicated that mice immunised with
A5CP formed antibodies to the CM79-identified epitope (P¼0.018,
Wilcoxon signed ranks test, CP binding of immunised mouse
serum in presence and absence of CM79 antibody), whereas mice
immunised with MFECPHis or MFEdmCPHis showed no sig-
nificant response to the CM79-identified epitope in the same test
(P¼1.0 and 0.24, respectively). These results indicated not only
that modification of the CM79-identified epitope successfully
reduced its immunogenicity in mice but that the His-tag was as
effective a means of achieving this as the R162A and G412A
mutations.
Use of MFECPHis in a phase I clinical trial and the human
immune response to the CM79-identified epitope
MFECPHis was chosen for the clinical trial. Murine immunisations
indicated that the His-tag appeared to protect the CM79-identified
epitope independently and there was no apparent advantage in
further modification of the site by mutation. MFECPHis (This
clinical grade MFECPHis was renamed MFECP1 to distinguish it
from research grade MFECPHis.) was prepared to clinical grade,
which included further purification by size exclusion chromato-
graphy and was administered to patients in a Phase I/II trial of
ADEPT. Each patient received 5000Um
 2 of MFECPHis (approxi-
mately 50–100mg depending on individual weight and height)
followed by escalating doses of prodrug ZD2767P after clearance of
MFECPHis from blood. Patients were bled at 21–42 days after
treatment and their immune response to the CM79-identified
epitope was analysed. Biotinylated CM79 antibody was employed
for these studies, which allowed use of a simple competition ELISA
testing the ability of biotinylated CM79 antibody to bind CP in the
presence of patients’ sera. If the sera contain antibodies to the
CM79-identified epitope, then these compete with and reduce
binding of biotinylated CM79 antibody to CP on the plates. For
these experiments, CP was presented to the sera/biotinylated CM79
in two different ways to minimise risk of erroneous results
obtained by masking or conformational changes to epitopes when
attaching to the ELISA plates. In one set of experiments, plates
were coated directly with CP. In another set, plates were coated
with CEA that was used to capture MFECPHis or A5CP by the
antibody moiety, leaving the CP moiety of these molecules free for
interaction. Three HACA-positive sera and 10 HACA-negative sera
of patients treated with MFECPHis and eight HACA-positive
immune sera from the A5CP ADEPT trial were available for testing
in these assays, the results of which are shown in Figure 5A and B.
These results with both assays show that patients who received
constructs with unmodified CP (in A5CP) made antibodies to the
CM79-identified epitope through demonstration of competition of
their sera with biotinylated CM79 antibody for binding to CP.
However, patients who received MFECPHis did not have a
response to the CM79-identified epitope as there was no significant
reduction of biotinylated CM79 antibody binding to CP in the
assays. The difference between the patient groups was marked
(P¼0.00003, unpaired Student’s t-test reduced binding of
biotinylated CM79 antibody in the presence of sera from patients
after administration of A5CP compared to MFECPHis). This
provides experimental evidence that addition of a C-terminal His-
tag successfully modifies the CM79-identified epitope to reduce its
immunogenicity in patients as observed with mice.
Murine polyclonal antibody response to repeated CP
administration
The polyclonal antibody response to CP was measured by ELISA
14 days after each immunising injection of MFECPHis,
MFEdmCPHis or A5CP. Results from these experiments, illu-
strated in Figure 6, show that Balb/c mice immunised with
MFECPHis and MFEdmCPHis had no detectable anti-CP anti-
bodies after a single injection, but developed progressively higher
levels of antibody after 2, 3, and 4 immunisations with these
molecules. Statistical analysis indicated that there was no
significant difference in the time taken for development of mouse
anti-CP antibodies to MFECPHis and the time taken for
development of mouse anti-CP to MFEdmCPHis (P¼0.203,
Fisher’s exact test). In contrast to these results, three out of eight
mice immunised with A5CP had a detectable anti-CP antibody
response after a single dose of A5CP and developed progressively
higher levels after further injections (Figure 6). Statistical
comparison of mice injected with MFECPHis and A5CP confirmed
that injections with MFECPHis can be repeated more times than
80 kDa
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40 kDa
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1      2      3
80 kDa
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40 kDa
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Figure 4 (A) SDS – PAGE and (B) Western blot of fusion proteins
expressed in E. coli (1) molecular weight markers (2) MFECP (3)
MFEdmCP. (C) SDS – PAGE and (D) Western blot fusion proteins
expressed in P. pastoris (4) MFECPHis (5) MFEdmCPHis (6) molecular
weight markers. Major band representing fusion proteins indicated by
arrow.
Immune response to an immunodominant B-cell epitope
A Mayer et al
2407
British Journal of Cancer (2004) 90(12), 2402–2410 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
swith A5CP prior to measurable antibodies to CP (P¼0.077,
Fisher’s exact test).
Human polyclonal antibody response to CP
Serum of patients after treatment with MFECPHis was tested for
polyclonal HACA formation using a validated anti-CP ELISA
developed to monitor the ADEPT clinical trial. Results from these
experiments showed that only 23% of patients (three out of 13)
treated with MFECPHis had detectable HACA after a single
administration of MFECPHis (Figure 7), while 97% (36/37) of
patients had detectable HACA when treated with A5CP in previous
trials (Napier et al, 2000; Francis et al, 2002). Fisher’s exact test
confirmed statistical significance (Po0.0001) between the HACA
response of these two patient groups.
DISCUSSION
Protein therapeutics form an important part of cancer therapy.
Antibodies, cytokines, immunotoxins and enzymes are in routine
clinical use and many developing treatments are antibody-based
(Carter, 2001; Glennie and van de Winkel, 2003; Hudson and
Souriau, 2003). Emergence of these antibody-based therapies has
been facilitated by developments in technology, which have largely
addressed the limitation of immunogenicity of antibodies by
methods such as chimerisation, humanisation and even produc-
tion of completely human antibodies (Winter and Milstein, 1991;
Carter, 2001; Glennie and van de Winkel, 2003). However, in
strategies where the antibody arm is used to target bacterial
enzymes or toxins, therapy is still limited by development of an
antibody response to the effector arm. These targeted therapies
have potential to greatly reduce the systemic toxicity of conven-
tional chemotherapy or radiotherapy, but repeated administration
is often required for effective therapy. The development of an
antibody response involves different cells of the immune system,
but the final common pathway involves expansion and differentia-
tion of B-cells with antibody receptors capable of binding to
epitopes on the protein therapeutic. Elimination of all immuno-
genic epitopes from a protein would be a laborious and possibly
unachievable task, but a number of approaches have been pursued
to circumvent the antibody response by modifying the adminis-
tered protein to minimise its immunogenicity (Chirino et al, 2004).
For example, site-specific pegylation has been successful for an
immunotoxin used in cancer therapy (Tsutsumi et al, 2000) and
may reduce the immunogenicity of streptavidin that has been used
to improve therapeutic ratios in radioimmunotherapy (Chinol et al,
1998). Replacement of foreign sequences by human sequence has
reduced, although not entirely eliminated antibody formation to
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Figure 5 (A) Inhibition of binding of biotinylated CM79 antibody by sera
of patients after administration of MFECPHis and A5CP. Binding of CM79
antibody in immunised sera was compared to CM79 antibody binding in
normal human serum. Statistical comparison of the reduction of CM79
antibody binding after treatment with A5CP with the reduction of CM79
antibody binding after treatment with MFECPHis was significant
(P¼0.00003 for the comparison of all available sera after administration
of MFECPHis and A5CP; P¼0.023 for the comparison of HACA-positive
sera only, unpaired Student’s t-test). (B) Results were confirmed on CP-
coated plates (P¼0.0001 for the comparison of all available sera after
administration of MFECPHis and A5CP, P¼0.03 for the comparison of
HACA-positive sera only, unpaired Student’s t-test). Bars indicate standard
deviation.
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Figure 6 Anti-CP antibody formation in mice after 50mg MFECPHis (A),
MFEdmCPHis (B) and A5CP (C) i.p. every 14 days for four doses.
Individual bars represent mice with measurable anti-CP antibodies in each
group of eight mice. Comparison of the number of injections prior to a
measurable anti-CP antibody response showed no statistically significant
difference between groups injected with MFECPHis and MFEdmCPHis
(P¼0.203; Fisher’s exact test), while comparison of the groups immunised
with A5CP and MFECPHis showed a statistical trend indicating that
injections could be repeated more frequently after MFECPHis compared to
A5CP (P¼0.077; Fisher’s exact test).
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stherapeutic antibodies and cytokines (Richards et al, 1999;
Casadevall et al, 2002; Welt et al, 2003). The ability to retain
activity while reducing immunogenicity is a key element for
success of targeted therapies and is more likely achieved for non-
human proteins by mutations in immunogenic epitopes, since this
requires minimal change in sequence and structure. In this
manuscript, we explore a method to achieving this for MFECP.
MFECP is a multifunctional protein designed for ADEPT, a
pretargeted cancer therapy. Reducing immunogenicity of this
protein is a particular challenge as the immune response to CP, the
bacterial enzyme, which forms part of MFECP, is vigorous. Hence
repeated treatment with ADEPT, which is ultimately necessary to
achieve effective therapy, has previously only been possible with
cyclosporin immunosuppression, which carries the potential of
unwanted side effects such as organ toxicity (Sharma et al, 1996).
Attempts to overcome this by engineering human carboxypepti-
dase have been elegant in principal but ineffective in vivo (Wolfe
et al, 1999).
We proposed that the immunogenicity of MFECP could best be
reduced by modifying a B-cell epitope. B-cell epitopes are often
located at a small number of sites on the surface of a protein and,
as mentioned above epitope disruption potentially requires only a
single amino-acid change. Furthermore, modification of B-cell
epitopes is particularly attractive for proteins, where the number of
repeat treatments is expected to be limited such as CP for ADEPT.
While repeated administration with modified protein may
eventually elicit an antibody response to a different set of epitopes,
there are at least two different ways in which progressive
development of this approach might allow clinically meaningful
repetition of treatment in cancer patients with immunogenic
proteins. First, modified proteins or totally different proteins with
the same function could be used in rotation or sequence so that
any antibody response made to a previously used protein would
not neutralise a subsequent protein that shares no immunogenic
epitopes. Second, is to reduce the ‘danger’ signal provided by
protein antigens (Matzinger, 2002). In this situation, a reduction of
strongly immunogenic epitopes for either B cells or Th cells could
lead to anergy or tolerance towards minor immunogenic epitopes
in a noninflammatory situation. The experience with monoclonal
antibodies supports this approach in that murine monoclonal
antibodies were strongly immunogenic and led to elimination of
the monoclonal antibodies within 14 days in most nonimmuno-
suppressed patients. Chimerisation of murine monoclonal anti-
bodies still left 15% of the murine variable region sequences
present in the chimeric monoclonal antibody, yet there was a
dramatic fall in immunogenicity and antibody production. Indeed,
clinical experience has failed to show any clinically significant
benefit for humanisation in which the residual murine comple-
mentarity determining region sequences comprise 7% compared
to chimerisation (Baert et al, 2003; Welt et al, 2003). This suggests
that the constant region of monoclonal antibodies contain the
most strongly immunogenic epitopes and its removal, although
not removing all potentially immunogenic epitopes, reduces the
‘danger’ signal sufficiently that they are much less likely to trigger
an antibody response.
Identification of B-cell epitopes by hybridoma technology has
been laborious in the past, but feasibility has vastly improved due
to the availability of a generic method for rapid recognition of B-
cell epitopes based on a phage display library of scFv antibodies,
surface enhanced laser desorption and ionisation (SELDI) affinity
mass spectrometry and bioinformatics tools as described pre-
viously by our group (Spencer et al, 2002). The CM79 site, a
surface-exposed conformational B-cell epitope comprising the C-
terminus and an internal sequence of CP has been identified by
this method and we have shown previously that the human
antibody response to CP is substantially directed towards this
CM79 site. In the current paper, we show that modification of the
CM79-identified epitope of CP could be achieved by mutation or
by addition of a C-terminal His-tag on the recombinant fusion
protein MFECP. Both of these modifications resulted in reduced
antibody formation to the CM79-identified epitope. In addition, a
delayed antibody response to CP in mouse and a significant
reduction of HACA formation in man was seen.
The strategy of mutating B-cell epitopes to reduce immuno-
genicity has also been applied with success by other workers for
staphylokinase (Collen et al, 1996) and L-asparaginase (Moola et al,
1994). This is however, to our knowledge, the first reported
instance of successful masking of an immunogenic epitope by
addition of a His-tag. His-tags are usually added to proteins for
purification purposes and are not widely reported to affect protein
function, although Goel et al (2000), have observed that the
addition of a His-tag to a scFv antibody appeared to interfere with
its antigen-binding. The experimental observations made by these
workers were supported by molecular modelling and are consistent
with our results that indicate an ability of His-tags to adopt
conformational states, which interfere with protein–protein
interactions.
Other factors affecting the formation of an antibody response to
CP need nevertheless to be considered. Firstly, an immunoreactive
T-cell epitope may be involved in the mutated region as recently
described for B-cell epitope modified staphylokinase (Warmerdam
et al, 2002). However, while mutation may potentially affect a Th-
cell epitope, addition of the C-terminal His-tag is unlikely to have
the same effect. Other factors known to affect neutralising
antibody formation include the route of administration, dosage
regimen, presence of endotoxins and aggregation (Braun et al,
1997). Route of administration and dosage regimen were
equivalent for all tested proteins and endotoxins, which are known
to increase the immunogenicity of proteins are unlikely to
contribute to the differences we observed because all proteins
tested in this study had a similar endotoxin content. However,
MFECPHis is glycosylated with mannose following expression in P.
pastoris and A5CP is not. Glycosylation may mask immunogenic
epitopes or affect protein conformation. Also, MFECPHis cleared
from circulation within 24h, while A5CP takes several days and
MFECPHis was confirmed to be monomeric, while aggregation due
to the process of chemical conjugation may contribute to the
antibody formation after A5CP. These parameters may contribute
to the immune response to the whole molecule and will be
investigated in later experiments, but do not explain the lack of the
antibody response to the CM79 site.
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Figure 7 HACA formation in patients 42 days after single administration
of MFECPHis, each bar represents an individual patient, the dashed line
indicates the cutoff for HACA positive sera. Three standard deviations
were added to the mean of a pool of pretreatment sera diluted 1/100 to
give the cutoff for HACA-positive sera.
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sIn conclusion, reduced antibody formation to the CM79-
identified epitope was observed in mice and men after modifica-
tion by mutation and addition of a C-terminal His-tag. This was
accompanied by a reduced antibody formation to CP, which could
allow repeated treatment with ADEPT. Modification of B-cell
epitopes appear to be a useful strategy for the reduction of
immunogenicity to foreign proteins and may have generic
application, in particular for recombinant cancer therapeutics,
which are not intended for protracted use.
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